Research map: Clinical Relevance of Bile Acid and Bile Acid-Related Therapy in Liver Cirrhosis: A Review

Back to the article

Papers in this map

  1. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial · Brent A. Neuschwander‐Tetri · 2014 · 2234 citations · Cited by this paper
  2. Factors Associated with Favorable One-Year Outcomes After PreserFlo MicroShunt Implantation: Insights from Anterior Segment Optical Coherence Tomography · 2026 · Related
  3. Global burden of liver disease: 2023 update · Harshad C. Devarbhavi · 2023 · 2217 citations · Cited by this paper
  4. Uncontrolled Hypertension Prevalence, Characteristic Profiles, and Risk of Cardiorenal and Metabolic Outcomes: Insights from the EnligHTN Study · 2026 · Related
  5. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial · Zobair M. Younossi · 2019 · 1263 citations · Cited by this paper
  6. Diagnostic Delay in Multiple Sclerosis in China: A Nationwide Cross-Sectional Study · 2026 · Related
  7. Pleiotropic Roles of Bile Acids in Metabolism · Thomas Q. de Aguiar Vallim · 2013 · 1233 citations · Cited by this paper
  8. Usability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study · 2026 · Related
  9. Bile acids and the gut microbiota: metabolic interactions and impacts on disease · Stephanie L. Collins · 2022 · 1204 citations · Cited by this paper
  10. Assessment of the MFSAF v4.0 and PROMIS Fatigue 7a to Measure Outcomes in Myelofibrosis: Validation from a Non-interventional Mixed Methods Study · 2026 · Related
  11. Global epidemiology of cirrhosis — aetiology, trends and predictions · Daniel Q. Huang · 2023 · 841 citations · Cited by this paper
  12. Long-Term Effects of Exercise During Pregnancy on the Metabolic Health of Mothers with Overweight/Obesity and Their Offspring: An 8- to 10-Year Follow-Up Study · 2026 · Related
  13. Interaction of gut microbiota with bile acid metabolism and its influence on disease states · Christopher M. Staley · 2016 · 597 citations · Cited by this paper
  14. Expert Consensus on the Clinical Application of Sulodexide in Vascular Diseases · 2026 · Related
  15. Countdown to 2030: eliminating hepatitis B disease, China · Jue Liu · 2019 · 495 citations · Cited by this paper
  16. An Eight-Century Evolution of Asthma Therapeutics in Western Countries: From Medieval Regimens to Anti-inflammatory Reliever Therapy and Precision Biologics · 2026 · Related
  17. Primary sclerosing cholangitis · Jessica Katharine Dyson · 2018 · 486 citations · Cited by this paper
  18. Budget Impact of Eplerenone for Heart Failure with Reduced Ejection Fraction: National Perspective and Regional Implications in Italy · 2026 · Related
  19. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology · Claudia Daniela Fuchs · 2022 · 481 citations · Cited by this paper
  20. Obstetric and Neonatal Factors Associated with Postpartum Depressive Symptoms: A Retrospective Multicenter EPDS-Based Study · 2026 · Related
  21. Hepatocellular carcinoma · Daniel F. Schafer · 1999 · 454 citations · Cited by this paper
  22. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids · Puneet Puri · 2017 · 427 citations · Cited by this paper
  23. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease · Marialena Mouzaki · 2016 · 393 citations · Cited by this paper
  24. Randomized Placebo-Controlled Trial of Ursodeoxycholic Acid With Vitamin E in Nonalcoholic Steatohepatitis · Jean‐François Dufour · 2006 · 358 citations · Cited by this paper
  25. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines · Gideon Morris Hirschfield · 2018 · 346 citations · Cited by this paper
  26. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial · Keyur Patel · 2020 · 338 citations · Cited by this paper
  27. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis · Brian C. Ferslew · 2015 · 337 citations · Cited by this paper
  28. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis · Peter Fickert · 2017 · 296 citations · Cited by this paper
  29. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis · Maren H. Harms · 2019 · 289 citations · Cited by this paper
  30. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma · Yau-Tuen Chan · 2024 · 280 citations · Cited by this paper
  31. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases · You Li · 2017 · 263 citations · Cited by this paper
  32. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis · Michael A Trauner · 2019 · 262 citations · Cited by this paper
  33. Acute-on-Chronic Liver Failure Clinical Guidelines · Jasmohan Singh Bajaj · 2022 · 246 citations · Cited by this paper
  34. Nonalcoholic Fatty Liver Disease · Xiao‐Jing Wang · 2018 · 229 citations · Cited by this paper
  35. Bile acid metabolism and signalling in liver disease · Claudia Daniela Fuchs · 2024 · 225 citations · Cited by this paper
  36. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial · Naim Alkhouri · 2022 · 220 citations · Cited by this paper
  37. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis · Katharina Brandl · 2018 · 218 citations · Cited by this paper
  38. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial · Richard J. Thompson · 2022 · 194 citations · Cited by this paper
  39. Obesity, fatty liver disease and intestinal microbiota · Nur Arslan · 2014 · 191 citations · Cited by this paper

Source: OpenAlex (CC0)